​

AtriCure (ATRC) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

ATRC Stock Forecast

AtriCure (ATRC) stock forecast, based on 18 Wall Street analysts, predicts a 12-month average price target of $59.00, with a high of $64.00 and a low of $54.00. This represents a 42.48% increase from the last price of $41.41.

$20 $29 $38 $47 $56 $65 High: $64 Avg: $59 Low: $54 Last Closed Price: $41.41

ATRC Stock Rating

AtriCure stock's rating consensus is Buy, based on 18 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 18 Buy (100.00%), 0 Hold (0.00%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 18 0 18 Strong Sell Sell Hold Buy Strong Buy

ATRC Price Target Upside V Benchmarks

TypeNameUpside
StockAtriCure42.48%
SectorHealthcare Stocks 15.45%
IndustryMedical Instruments & Supplies Stocks15.15%

Price Target Trends

1M3M12M
# Anlaysts-12
Avg Price Target-$64.00$59.00
Last Closing Price$41.41$41.41$41.41
Upside/Downside-54.55%42.48%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Dec, 2545---9
Nov, 2545---9
Oct, 2545---9
Sep, 2545---9
Aug, 2545---9
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Oct 30, 2025William PlovanicCanaccord Genuity$64.00$35.4480.59%54.55%
Jul 30, 2025BTIG$54.00$35.1353.71%30.40%
Jul 31, 2024Rick WiseStifel Nicolaus$26.00$22.0018.18%-37.21%
Jul 31, 2024Matt O'BrienPiper Sandler$40.00$22.0081.82%-3.40%
Jul 31, 2024Marie ThibaultBTIG$53.00$22.00140.91%27.99%
May 02, 2024Mike MatsonNeedham$40.00$24.7661.55%-3.40%
May 02, 2024Marie ThibaultBTIG$58.00$24.76134.25%40.06%
Apr 23, 2024Suraj KaliaOppenheimer$32.00$22.7140.91%-22.72%
Feb 06, 2023Canaccord Genuity$81.00$47.2071.61%95.60%
Dec 19, 2022Mike MatsonNeedham$58.00$41.3740.20%40.06%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Oct 30, 2025Canaccord GenuityBuyBuyhold
Oct 30, 2025CitigroupMarket OutperformMarket Outperformhold
Mar 27, 2025BTIGBuyBuyhold
Jan 22, 2025NeedhamBuyBuyhold
Oct 30, 2024OppenheimerOutperformOutperformhold
Oct 30, 2024UBSBuyBuyhold
Jul 31, 2024NeedhamUnderperformUnderperformhold
Jul 31, 2024Piper SandlerOverweightOverweighthold
Jul 31, 2024BTIGBuyBuyhold
Jul 08, 2024NeedhamUnderperformUnderperformhold

Financial Forecast

EPS Forecast

Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-1.14$1.11$-1.02$-0.66$-0.95----
Avg Forecast$-0.99$0.83$-1.10$-0.73$-0.81$-0.62$-0.42$-0.42$-0.35
High Forecast$-0.99$0.84$-1.09$-0.73$-0.77$-0.57$-0.34$-0.42$-0.35
Low Forecast$-1.01$0.82$-1.11$-0.74$-0.85$-0.67$-0.56$-0.42$-0.35
Surprise %15.15%33.73%-7.27%-9.59%17.28%----

Revenue Forecast

$200M $340M $480M $620M $760M $900M Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$206.53M$274.33M$330.38M$399.25M$465.31M----
Avg Forecast$206.91M$273.69M$330.14M$396.44M$461.97M$522.48M$589.16M$718.70M$850.60M
High Forecast$208.79M$276.18M$332.81M$398.42M$465.32M$525.07M$589.16M$724.96M$858.01M
Low Forecast$205.42M$271.72M$327.97M$394.46M$460.52M$519.13M$589.16M$713.96M$844.99M
Surprise %-0.18%0.24%0.07%0.71%0.72%----

Net Income Forecast

$-100M $-50M $0 $50M $100M $150M Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-48.16M$50.20M$-46.47M$-30.44M$-44.70M----
Avg Forecast$-54.26M$70.11M$85.09M$-30.44M$-38.92M$-29.69M$-20.07M$-19.48M$-16.21M
High Forecast$-43.41M$101.87M$118.43M$-18.51M$-35.67M$-26.37M$-15.56M$-19.28M$-16.07M
Low Forecast$-65.11M$38.35M$51.75M$-42.36M$-39.29M$-30.92M$-25.94M$-19.67M$-16.39M
Surprise %-11.25%-28.40%-154.61%-14.85%----

ATRC Forecast FAQ

Is AtriCure stock a buy?

AtriCure stock has a consensus rating of Buy, based on 18 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 18 Buy, 0 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that AtriCure is a favorable investment for most analysts.

What is AtriCure's price target?

AtriCure's price target, set by 18 Wall Street analysts, averages $59 over the next 12 months. The price target range spans from $54 at the low end to $64 at the high end, suggesting a potential 42.48% change from the previous closing price of $41.41.

How does AtriCure stock forecast compare to its benchmarks?

AtriCure's stock forecast shows a 42.48% upside, outperforming the average forecast for the healthcare stocks sector (15.45%) and outperforming the medical instruments & supplies stocks industry (15.15%).

What is the breakdown of analyst ratings for AtriCure over the past three months?

  • December 2025: 44.44% Strong Buy, 55.56% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • November 2025: 44.44% Strong Buy, 55.56% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • October 2025: 44.44% Strong Buy, 55.56% Buy, 0% Hold, 0% Sell, 0% Strong Sell.

What is AtriCure’s EPS forecast?

AtriCure's average annual EPS forecast for its fiscal year ending in December 2025 is $-0.62, marking a -34.74% decrease from the reported $-0.95 in 2024. Estimates for the following years are $-0.42 in 2026, $-0.42 in 2027, and $-0.35 in 2028.

What is AtriCure’s revenue forecast?

AtriCure's average annual revenue forecast for its fiscal year ending in December 2025 is $522.48M, reflecting a 12.29% increase from the reported $465.31M in 2024. The forecast for 2026 is $589.16M, followed by $718.7M for 2027, and $850.6M for 2028.

What is AtriCure’s net income forecast?

AtriCure's net income forecast for the fiscal year ending in December 2025 stands at $-29.689M, representing a -33.58% decrease from the reported $-44.698M in 2024. Projections indicate $-20.072M in 2026, $-19.477M in 2027, and $-16.208M in 2028.